

**Disclaimer:** The following bibliography is prepared as a courtesy for our customers to identify recently published works relevant to the on-label use of the Xpert Bladder Cancer Monitor Test.

### PUBLICATIONS

Kavcic N, et al. **Clinical Evaluation of Two Non-Invasive Genetic Tests for Detection and Monitoring of Urothelial Carcinoma: Validation of UroVysion and Xpert Bladder Cancer Detection Test.** Front Genet. 2022 Jun 6;13:839598. doi:[10.3389/fgene.2022.839598](https://doi.org/10.3389/fgene.2022.839598)

Fasulo V, et al. **Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under “Active Surveillance” for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study.** Front Oncol. 2022 Jan 27;12:832835. doi:[10.3389/fonc.2022.832835](https://doi.org/10.3389/fonc.2022.832835)

Singer G, et al. **The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT® Bladder Cancer Monitor and Narrow Band Imaging® Cystoscopy.** Cancers (Basel). 2022 Jan 26;14(3):618. doi:[10.3390/cancers14030618](https://doi.org/10.3390/cancers14030618)

Cancel-Tassin G, et al. **Assessment of Xpert Bladder Cancer Monitor Test Performance for the Detection of Recurrence during Non-Muscle Invasive Bladder Cancer Follow-up.** World J Urol. 2021 Mar 26; 1–7. doi:[10.1007/s00345-021-03629-1](https://doi.org/10.1007/s00345-021-03629-1)

Cowan B, et al. **Longitudinal Follow-up and Performance Validation of an mRNA-based Urine Test (Xpert Bladder Cancer Monitor) for Surveillance in Patients with Non-Muscle-Invasive Bladder Cancer.** BJU 2021. doi:[10.1111/bju.15418](https://doi.org/10.1111/bju.15418)

D’Elia C, et al. **Diagnostic Value of Xpert Bladder Cancer Monitor in the Follow-up of Patients Affected by Non-Muscle Invasive Bladder Cancer: An Update.** Ther Adv Urol. 2021 Jan–Dec; 13. doi:[10.1177/1756287221997183](https://doi.org/10.1177/1756287221997183)

Trenti E, et al. **Comparison of 2 New Real-Time Polymerase Chain Reaction-Based Urinary Markers in the Follow-up of Patients With Non-Muscle-Invasive Bladder Cancer.** Cancer Cytopathol. 2020 May;128(5):341–347. doi:[10.1002/cncy.22246](https://doi.org/10.1002/cncy.22246)

Van Valenberg FJP, et al. **Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.** Eur Urol. 2019 May;75:853-60. doi:[10.1016/j.eururo.2018.11.055](https://doi.org/10.1016/j.eururo.2018.11.055)

D’Elia C, et al. **Diagnostic Predictive Value of Xpert Bladder Cancer Monitor in the Follow-up of Patients Affected by Non-Muscle Invasive Bladder Cancer.** J Clin Pathol. 2018 Feb;0: 1–5. doi:[10.1136/jclinpath-2018-205393](https://doi.org/10.1136/jclinpath-2018-205393)

Pichler R, et al. **Increased Accuracy of a Novel mRNA-Based Urine Test for Bladder Cancer Surveillance.** BJU Int. 2018 Jan;121(1):29-37. doi:[10.1111/bju.14019](https://doi.org/10.1111/bju.14019)

Wallace E, et al. **Development of a 90-Minute Integrated Non-Invasive Urinary Assay for Bladder Cancer Detection.** J Urol. 2018 Mar;199(3):655–662. doi:[10.1016/j.juro.2017.09.141](https://doi.org/10.1016/j.juro.2017.09.141)

## Xpert Bladder Cancer Monitor Bibliography (continued)

### POSTERS

Fasulo V, et al. **Xpert Bladder Monitor: Longitudinal Clinical Performance for Avoiding Un-Necessary Cystoscopies in Patients Under Active Surveillance for Recurrent Bladder Cancer (BIAS project)**. Poster presented at Annual Meeting of the European Association of Urology, 2021 July 8–12.

D'Elia C, et al. **Xpert Bladder Cancer Monitor and Bladder Epicheck<sup>®</sup> in the Follow Up of Patients Affected by Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC): Preliminary Data**. Poster presented at Annual Meeting of the European Association of Urology, 2021 July 8–12.

Cancel-Tassin G, et al. **The Performance of the Xpert Bladder Cancer Monitor Urine Test is Superior to that of Cytology for the Detection of Non-Muscle Invasive Bladder Cancer Recurrences**. Poster presented at Annual Meeting of the Association of French Urologists. 2020 Nov 18–21.

Trabelssi M, et al. **Diagnostic Performance of the Xpert Bladder Cancer Monitor Urine Assay in the Monitoring of Patients With Non-Muscle Infiltrating Bladder Cancers: Interim Results From a Prospective Study**. Poster presented at Annual Meeting of the Association of French Urologists. 2020 Nov 18–21.

D'Elia C, et al. **Xpert Bladder Cancer Monitor in the Follow Up of Patients Affected by Non-Muscle Invasive Bladder Cancer (NMIBC): an Update**. Poster presented at Annual Meeting of the European Association of Urology. 2020 Jul 17–21.

Hurle R, et al. **Clinical Performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based Urine Test, in Active Surveillance (AS) Patients with Recurrent Non-Muscle Invasive Bladder Cancer (NMIBC): Results from the Bladder Cancer Italian Active Surveillance (BIAS) Project**. Poster presented at Annual Meeting of the European Association of Urology. 2020 Jul 17–21.

Elsawy A, et al. **Diagnostic and Predictive Capacity of a Novel mRNA-based Urine Test (Xpert Bladder Cancer Monitor) for Surveillance in Non-Muscle Invasive Bladder Cancer; Single Center Study**. Poster presented at Annual Meeting of the European Association of Urology. 2020 Jul 17–21.

Ramos Soler D, et al. **Evaluación de la Plataforma GeneXpert<sup>®</sup> Para la Detección y Monitorización de la Recurrencia del Cáncer de Vejiga**. Poster presented at the Annual Meeting of SEAP-IAP, SEC and SEPAF 2019 May 22–24. Granada, Spain. (only available in Spanish)

Hurle R, et al. **Xpert Bladder Monitor Test for Failure Definition of Patients Under Active Surveillance for Recurrence Low-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)**. Abstract presented at the Annual Meeting of the American Urological Association. 2019 May 3–6. Chicago, USA.

Cancel-Tassin G, et al. **Evaluation of Non-Muscle Invasive Bladder Recurrence Using mRNA-based Urine Test (Xpert Bladder Cancer Monitor) and Cytology**. Poster presented at Annual Meeting of the European Association of Urology. 2019 Mar 15–19. Barcelona, Spain.

CE-IVD. *In Vitro* Diagnostic Medical Device. Not available in all countries.

#### CORPORATE HEADQUARTERS

904 Caribbean Drive  
Sunnyvale, CA 94089 USA

TOLL FREE +1.888.336.2743  
PHONE +1.408.541.4191  
FAX +1.408.541.4192

#### EUROPEAN HEADQUARTERS

Vira Solelh  
81470 Maurens-Scopont France

PHONE +33.563.82.53.00  
FAX +33.563.82.53.01  
EMAIL [cepheid@cepheideurope.fr](mailto:cepheid@cepheideurope.fr)

[www.Cepheidinternational.com](http://www.Cepheidinternational.com)

© 2022 Cepheid. 5100-01